Ablation Outperforms Antiarrhythmic Drugs in Symptomatic Atrial Fibrillation. This Is the Clinical Decision.

The Scene

The following scene is drawn from the composite of patients I have cared for in clinic and on the hospital floor. All identifying details are changed.

Jennifer is 46 years old, a physical therapist from Champaign, Illinois. For three years she has been in and out of the emergency department with paroxysmal atrial fibrillation. Her episodes last 4 to 18 hours. They begin without warning: her heart is pounding out of rhythm, she is short of breath, she cannot exercise, she cannot focus. She converted spontaneously each time, twice after IV adenosine, once after electrical cardioversion at 2 AM.

She is on flecainide 100 mg twice daily, which has reduced her episode frequency from roughly monthly to roughly quarterly. But the most recent episode broke through the flecainide. Her cardiologist in Champaign is now referring her to an electrophysiologist in Chicago.

The electrophysiologist explains: “We can burn the sleeves of tissue around your pulmonary veins that are firing these abnormal beats and triggering your AF. You’ll be under sedation. The procedure takes 2 to 3 hours. Most patients get 50 to 70% reduction in recurrence at 1 year. About 30% need a repeat procedure.”

Jennifer wants to understand more than the numbers. She wants to understand what burning means, where the pulmonary veins are, and why isolation of those structures stops the arrhythmia.

This article is for Jennifer.

What It Is

Cardiac catheter ablation is a procedure in which radiofrequency energy (heat) or cryotherapy (cold) is delivered through a catheter to specific areas of cardiac tissue to permanently disrupt abnormal electrical circuits or ectopic firing sites.

The term “ablation” derives from the Latin ablatio, meaning removal. In cardiac ablation, tissue is not physically removed; it is rendered electrically inert through thermal injury. At radiofrequency energy temperatures of 50 to 70 degrees Celsius, cell death occurs within seconds, creating a permanent scar that does not conduct electrical impulses 5 / Solid 80022-3).

Cryoablation uses liquid nitrogen to cool the catheter tip to -40 to -80 degrees Celsius. Freeze-thaw cycles also create permanent injury, with the safety advantage that the catheter adheres to tissue during freezing (the “cryoadhesion” effect) and injury is stopped if the freeze is terminated before the cell death threshold is reached. Cryoablation is the dominant technology for pulmonary vein isolation in many centers, using a balloon catheter (Arctic Front Advance, Medtronic) rather than a point-by-point radiofrequency catheter.

What Ablation Treats

Ablation is used for:

• Atrial fibrillation (pulmonary vein isolation): The most common and the most complex ablation indication; 450,000+ procedures annually in the US and growing.
• Atrial flutter (CTI ablation): Typical right atrial flutter; ablation of the cavotricuspid isthmus (CTI). Cure rates above 95% 5 / Solid 00596-X).
• Supraventricular tachycardia (AVNRT, AVRT, atrial tachycardia): Cure rates 90 to 97% depending on mechanism 5 / Solid .
• Ventricular tachycardia (scar-based VT): VT substrate modification in ischemic cardiomyopathy; VT storm ablation.
• Idiopathic PVCs/VT: Outflow tract (RVOT or LVOT) ablation.

The Mechanism

The Pulmonary Vein Trigger Hypothesis

Haissaguerre and colleagues demonstrated in 1998 that the majority of paroxysmal AF initiating triggers arise from ectopic foci within the muscular sleeves of cardiac tissue that extend 2 to 3 cm into the pulmonary veins 5 / Solid . This observation changed the understanding of AF from a random electrical storm into a targetable, anatomically specific arrhythmia. It is one of the most consequential discoveries in electrophysiology of the 20th century.

The pulmonary veins enter the left atrium posteriorly: two left veins (left superior, left inferior) and two right veins (right superior, right inferior). Each is surrounded by a cylindrical sleeve of cardiomyocytes with automaticity properties distinct from normal atrial myocardium. Stimulation or spontaneous firing of these sleeve cells fires electrical impulses that enter the left atrium and, in susceptible patients, trigger the reentrant AF.

Pulmonary Vein Isolation

Pulmonary vein isolation (PVI) encircles each pulmonary vein (or the ipsilateral veins in pairs) with a continuous line of ablation lesions at the atrial-PV junction, electrically disconnecting the sleeve from the left atrium. When the sleeve fires after isolation, the impulse cannot enter the atrium; the trigger cannot ignite AF.

PVI does not eliminate AF drivers that arise from within the left atrial body, the posterior wall, the LAA, or the right atrium. In persistent and long-standing persistent AF, non-PV triggers and left atrial substrate (fibrosis, reentrant drivers) may require additional ablation beyond PVI alone 5 / Solid .

Radiofrequency Ablation

A mapping catheter (typically 3.5 mm irrigated-tip) is navigated to the target site using 3D electroanatomic mapping (CARTO, Biosense Webster; EnSite X, Abbott). Contact force sensing enables real-time measurement of the catheter-tissue interface force; inadequate force produces superficial lesions that recover; excessive force risks steam pop, perforation, or PV stenosis 5 / Solid . Modern ablation catheters incorporate contact force monitoring, reducing transmural lesion failure rates.

Pulsed field ablation (PFA) is a newer energy modality using high-voltage electrical pulses (electroporation) to create irreversible electroporation of cell membranes, causing cell death without thermal injury. PFA is cardiomyocyte-selective (due to the unique electrical properties of cardiomyocytes versus fibroblasts, smooth muscle, and phrenic nerve) 4 / Promising . Early trial data show PFA-based PVI has equivalent efficacy to radiofrequency and cryoablation with fewer esophageal thermal injuries.

Cryoballoon Ablation

The cryoballoon is a spherical balloon catheter that occludes each pulmonary vein ostium and delivers circumferential cryotherapy to the entire vein-atrial junction simultaneously, rather than requiring point-by-point lesion delivery. Procedure time is typically shorter than irrigated-tip radiofrequency ablation for PVI; the FREEZE AF trial and the STOP-AF trial showed cryoballoon non-inferior to radiofrequency for 1-year AF freedom in paroxysmal AF 5 / Solid .

How It Is Used

Patient Selection for AF Ablation

AF ablation is appropriate in:

• Symptomatic paroxysmal or persistent AF who have failed or are intolerant of at least one antiarrhythmic drug (Class I, 2023 ACC/AHA AF Guidelines) 5 / Solid
• Paroxysmal AF as first-line therapy in preference to antiarrhythmic drug therapy (Class IIa for experienced centers)
• Heart failure with reduced EF and AF meeting CASTLE-AF criteria (Class IIa)
• AF with rapid ventricular response despite rate-controlling medications (Class IIa)

Unfavorable factors (higher recurrence risk after ablation):

• Long-standing persistent AF (AF continuously present for more than 12 months): 1-year success rates drop to 40 to 60% vs. 70 to 80% for paroxysmal AF
• Severe left atrial enlargement (LA diameter above 55 mm): predictor of recurrence
• Obesity (BMI above 35): higher AF burden and recurrence
• Sleep apnea (untreated): AF recurs if the trigger is not addressed
• Structural heart disease with severe LV dysfunction (but see CASTLE-AF)

The Pre-Ablation Workup

• 12-lead ECG and rhythm documentation
• Echocardiogram (LA size and function, LV function, valve assessment)
• TEE or CT of left atrium to rule out LAA thrombus before ablation (ablation in the presence of LAA thrombus risks embolization)
• Pulmonary function testing if planned for general anesthesia in a patient with significant lung disease
• Thyroid function (thyrotoxicosis mimics AF and must be treated first)
• Renal function (heparin and flush volumes are dosed accordingly)

The EP Lab Procedure

The patient is placed under conscious sedation or general anesthesia. Two or three sheaths are introduced into the right femoral vein. Transseptal puncture (with a Brockenbrough needle or radiofrequency energy-assisted technique) accesses the left atrium through the interatrial septum. A circular mapping catheter (Lasso, Biosense Webster, or equivalent) is positioned at each PV to record electrical isolation.

A 3D electroanatomical map of the left atrium is constructed using the mapping catheter and a reference electrode. Ablation catheter is navigated to the PV antrum. Lesion delivery proceeds circumferentially. Successful PVI is confirmed when all PV electrograms are eliminated and the PV no longer responds to left atrial pacing.

If additional ablation targets are planned (posterior wall isolation, LAA ablation, roof line, etc.) these follow PVI. Total procedure time is 90 to 180 minutes for paroxysmal AF; 2 to 4 hours for persistent AF with additional substrate modification.

Geographic Considerations

High-volume EP centers in central Illinois include OSF Saint Francis Medical Center in Peoria and the University of Illinois Health EP program in Chicago. Northwestern Medicine’s EP program (Chicago) performs more than 400 AF ablation procedures annually. For patients in the Champaign-Urbana area, Carle Foundation Hospital maintains an electrophysiology lab with ablation capability, primarily for lower-complexity cases; complex persistent AF ablation frequently requires referral to Chicago or Peoria. The 2-hour drive from Champaign to Chicago or Peoria is the realistic access barrier for many central Illinois patients.

The Evidence

CASTLE-AF: Ablation in HFrEF

CASTLE-AF (Marrouche NF, et al. N Engl J Med. 2018; doi:10.1056/NEJMoa1707855) enrolled 363 patients with paroxysmal or persistent/long-standing persistent AF and LVEF below 35%, randomized to ablation versus conventional medical therapy (rate or rhythm control pharmacotherapy). At median follow-up of 60.5 months, ablation reduced the primary endpoint of death or worsening heart failure:

• Ablation: 28.5%
• Medical therapy: 44.6%
• HR 0.62, 95% CI 0.43 to 0.87; p = 0.007 5 / Solid

Mortality alone: ablation 13.4% vs. medical therapy 25.0% (HR 0.53, 95% CI 0.32 to 0.86; p = 0.011) 5 / Solid . This was the first evidence that ablation reduces mortality in AF patients with heart failure. The effect size was larger than any antiarrhythmic drug trial in HFrEF. What CASTLE-AF did not show: it was a small trial (363 patients), and the HFrEF population was highly selected. The relative benefit was large but the absolute event rates were high, suggesting this was a sick population. The results require replication in larger trials.

CABANA: Ablation vs. Drug Therapy in the General AF Population

CABANA (Packer DL, et al. JAMA. 2019; doi:10.1001/jama.2019.0692) enrolled 2,204 patients with newly diagnosed or undertreated AF randomized to ablation versus antiarrhythmic drug therapy. On intention-to-treat analysis, the primary composite endpoint of death, disabling stroke, serious bleeding, or cardiac arrest did not differ significantly (5.2% ablation vs. 6.1% drug therapy; HR 0.86, 95% CI 0.65 to 1.15; p = 0.30) 5 / Solid .

CABANA interpretation controversy: a 27.5% crossover rate from the drug therapy arm to ablation diluted the intent-to-treat analysis. Per-protocol analysis showed ablation reduced MACE by 27% (HR 0.73, 95% CI 0.54 to 0.99; p = 0.04) 4 / Promising . Quality-of-life measures (AFEQT score, MAYO-AF score) showed significantly better outcomes with ablation at 12 months. CABANA established that ablation is superior to drug therapy for symptom control and quality of life, even if the mortality signal requires further data.

EAST-AFNET 4: The Case for Early Rhythm Control

EAST-AFNET 4 (Kirchhof P, et al. N Engl J Med. 2020; doi:10.1056/NEJMoa2019422) enrolled 2,789 patients with early AF (diagnosed less than 1 year) and cardiovascular conditions randomized to early rhythm control (antiarrhythmic drugs or ablation) versus usual care (rate control with rhythm control only for symptoms). At 5.1 years median follow-up, early rhythm control reduced the primary composite of CV death, stroke, or hospitalization for worsening heart failure or ACS (13.4% vs. 17.6%; HR 0.79, 95% CI 0.66 to 0.94; p = 0.005) 5 / Solid . Stroke specifically: 2.9% vs. 4.4% (HR 0.65, 95% CI 0.44 to 0.97) 5 / Solid . What EAST-AFNET 4 showed: early rhythm control, whether by drugs or ablation, reduces major events in AF patients with concurrent cardiovascular disease. This reframed the AFFIRM narrative (which showed no benefit from rhythm control) by demonstrating that early intervention differs from late intervention.

FIRE AND ICE: Cryoballoon vs. Radiofrequency

FIRE AND ICE (Kuck KH, et al. N Engl J Med. 2016; doi:10.1056/NEJMoa1602014) enrolled 762 patients with paroxysmal AF randomized to cryoballoon ablation (Arctic Front Advance) versus irrigated-tip radiofrequency ablation. At 1.5 years, the primary efficacy outcome of initial treatment failure (first recurrence, antiarrhythmic use, repeat ablation, or cardioversion) did not differ significantly (34.6% cryoballoon vs. 35.9% RF; p = 0.0015 for non-inferiority) 5 / Solid . Cryoballoon had shorter procedure time; RF had lower phrenic nerve palsy risk (2.7% vs. 0.6%). For paroxysmal AF, cryoballoon and radiofrequency are equivalent in efficacy.

Ablation for SVT: High Cure Rates

Catheter ablation for AVNRT (slow-fast re-entry using the AV node dual pathway system) achieves acute procedural success in 97 to 99% of cases with recurrence rates below 5% at 1 year 5 / Solid . Complete AV block (requiring pacemaker) occurs in approximately 0.5 to 1.5% of AVNRT ablations due to inadvertent injury to the compact AV node. For AVRT (accessory pathway-mediated SVT), cure rates are 93 to 98% with right-sided pathways and 90 to 95% with left-sided pathways.

Ablation for VT: VANISH Trial

VANISH (Sapp JL, et al. N Engl J Med. 2016; doi:10.1056/NEJMoa1606510) enrolled 259 patients with ischemic cardiomyopathy and VT that recurred or was poorly tolerated despite antiarrhythmic therapy, randomized to catheter ablation versus escalated antiarrhythmic therapy (increased dose of existing drug or switch to amiodarone). At a mean follow-up of 27.9 months, ablation reduced the primary composite of death, VT storm, or appropriate ICD shock (59.1% ablation vs. 68.5% escalated drug therapy; HR 0.72, 95% CI 0.53 to 0.98; p = 0.04) 5 / Solid . Ablation for VT in ischemic cardiomyopathy reduces the burden of appropriate ICD shocks and the cycle of VT recurrence.

Recurrence Rates After AF Ablation

Single-procedure 12-month freedom from AF (off antiarrhythmic drugs):

• Paroxysmal AF: 70 to 80% 5 / Solid
• Persistent AF: 55 to 70% 5 / Solid
• Long-standing persistent AF: 40 to 60% 4 / Promising

Multiple procedures improve cumulative freedom: by 3 to 5 years with 1.5 procedures on average, freedom from AF is approximately 80% for paroxysmal and 65% for persistent 4 / Promising .

The Patient Experience

Jennifer’s procedure was under general anesthesia (most centers now prefer general anesthesia over sedation for AF ablation due to better catheter stability with controlled breathing). Two transseptal sheaths. Point-by-point radiofrequency PVI with contact force monitoring. Total procedure time: 2 hours 45 minutes.

She woke up with mild chest soreness. She spent one night in the hospital. She was discharged on a 90-day anticoagulation course (apixaban) with the understanding that symptoms in the first 3 months do not predict 1-year outcome; the “blanking period” (first 90 days post-ablation) is characterized by inflammation-mediated arrhythmias that do not represent procedural failure.

What Your Cardiologist Will Not Have Time to Explain

• The 90-day blanking period means nothing counts. Any AF, flutter, or atrial arrhythmia in the first 90 days post-ablation is expected due to pericardial inflammation and healing. These episodes are not evidence that the ablation failed. This does not mean ignoring symptoms; it means not changing treatment based on early recurrence. At 90 days, a rhythm monitor is used to assess the true response.

• Anticoagulation continues for at least 90 days regardless of whether AF seems to be gone. Even asymptomatic AF carries stroke risk, and early post-ablation AF (even during the blanking period) requires continued anticoagulation protection. Stopping anticoagulation early because “the ablation worked” is the wrong decision.

• Approximately 30% of patients need a second procedure. This is not failure; it is expected and planned for. A repeat ablation addressing residual gaps in the PVI lines, non-PV triggers, or persistent atrial substrate typically has higher success than the initial procedure 4 / Promising .

• Complications, though rare, exist. The major procedural risks are: pulmonary vein stenosis (narrowing of a pulmonary vein from aggressive ablation at the vein-atrium junction; incidence less than 1% with antral ablation), atrioesophageal fistula (rare, approximately 0.03 to 0.05%, potentially fatal; mitigated by esophageal temperature monitoring), phrenic nerve palsy (right phrenic nerve injury during right PV ablation; 1 to 2% with cryoballoon, usually resolves within 6 to 12 months), and cardiac tamponade (0.5 to 1%) 5 / Solid .

• Esophageal monitoring. During AF ablation, the esophagus runs directly posterior to the left atrium. Thermal injury to the esophagus, if severe, can create a fistula to the left atrium, which carries approximately 60% mortality when it occurs. Centers monitor esophageal temperature and limit posterior wall energy delivery to mitigate this risk.

Sex Differences in AF Ablation

Women undergoing AF ablation have lower success rates than men in most observational studies, attributable to later presentation (more persistent AF), more advanced atrial fibrosis, and smaller LA dimensions in early disease 4 / Promising . Women have higher procedural complication rates in some registries, though this difference attenuates when adjusted for center volume and AF type. Whether biological sex independently predicts ablation outcome, independent of disease duration and fibrosis, remains under investigation.

Decisions and Trade-Offs

Ablation vs. Antiarrhythmic Drugs

For symptomatic paroxysmal AF, the 2023 ACC/AHA guidelines acknowledge ablation as reasonable first-line therapy (Class IIa) when the patient prefers it and an experienced operator is available. The historical requirement for “antiarrhythmic drug trial first” is no longer an absolute barrier. CABANA’s quality-of-life data, EAST-AFNET 4’s early-intervention benefit, and CASTLE-AF’s mortality data collectively make a strong case for early ablation in symptomatic patients with cardiovascular comorbidities.

For asymptomatic AF with preserved LV function, ablation’s benefit over rate control alone is uncertain. Asymptomatic AF detected on wearable monitoring is a scenario where the EAST-AFNET 4 data support early rhythm control, but whether ablation is superior to antiarrhythmic drugs in this context is not established by RCT.

The HFrEF Decision

CASTLE-AF established that ablation reduces mortality in AF with HFrEF. This is the most compelling ablation indication outside SVT/flutter. Patients with HFrEF who have AF should be considered for ablation if their anatomy is reasonable, their clinical status allows the procedure, and their AF is at least partially reversible (tachycardia-mediated cardiomyopathy, not pure ischemic scar).

The Three Questions Every Patient Should Ask

1. “How many AF ablation procedures does your program perform per year, and what is your single-procedure 12-month success rate for paroxysmal AF?” Programs performing more than 100 AF ablations per year have lower complication rates and higher success rates.

2. “Will you use contact force monitoring and 3D mapping, or is this a conventional non-force-sensing ablation?” Force sensing is now standard of care at high-volume centers; its absence is a reasonable marker of an under-resourced program.

3. “What is your esophageal monitoring protocol?” Given the severity of atrioesophageal fistula, every center should have a standardized approach to esophageal protection.

Clinical Synthesis

Jennifer’s AF at age 46 is early disease. She is paroxysmal. Her left atrium is not severely dilated. Her LV function is preserved. She is the ideal ablation candidate from a prognostic standpoint: the structural substrate that makes ablation fail has not yet developed.

The core clinical thesis on ablation is about the timing question. EAST-AFNET 4 showed that early rhythm control provides event reduction that late rhythm control does not. The patient who receives their first ablation at 47 with paroxysmal AF and a normal atrium has fundamentally different expected outcomes than the patient who presents at 62 with 15 years of undertreated AF and severe left atrial fibrosis.

If you have been offered ablation for AF: a structured cardiovascular assessment reviews whether this is the right time in the disease course, whether your medical therapy is truly improved, and whether the operator and center meet the volume criteria that predict successful outcome.

If you have AF that is currently controlled on medication but you are considering your long-term options: the Signal Check provides the framework for timing the ablation conversation: when does medical therapy become insufficient, and what markers predict impending ablation failure if it is delayed?

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.